Evidence map›Paper›PMID 35715592›Full record

ArticleScientific reports2022

Lipopolysaccharide-induced murine lung injury results in long-term pulmonary changes and downregulation of angiogenic pathways.

S T Tsikis, S C Fligor, T I Hirsch, A Pan, L J Yu, H Kishikawa, M M Joiner, P D Mitchell, M Puder

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Assessment of Noninvasive Measurement Techniques and Histologic Findings in a Mouse Model of LPS-Induced Acute Lung Injury.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026
    Article
  5. Article
  6. The Lectin fromInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

S T TsikisVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
S C FligorVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
T I HirschVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
A PanVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
L J YuVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
H KishikawaVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
M M JoinerVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
P D MitchellInstitutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, 02115, USA.
M PuderVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Mark.Puder@childrens.harvard.edu.
Harvard University · USBoston Children's Hospital · US

Funding

HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
RESEARCH TRAINING IN ALIMENTARY TRACT SURGERYT32DK007754 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HODIN, RICHARD A. · 1997 to 2025
$6.5M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
Harvard-Longwood Short-Term Research Training in Vascular SurgeryT35HL110843 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHRISTIANE FERRAN, FRANK W LOGERFO · 2013 to 2026
$609k
NHLBI NIH HHS T32 HL007734NHLBI NIH HHS T35 HL110843NICHD NIH HHS U54 HD090255NIDDK NIH HHS T32 DK007754NIH HHS 2T32DK007754-21NIH HHS 5T32HL007734NIH HHS 5T35HL110843
6 · The paper itself

Abstract

Acute respiratory distress syndrome is the most severe form of acute lung injury (ALI) and is associated with significant mortality. Lipopolysaccharide (LPS)-induced injury is a valuable murine model of ALI but there is a paucity of data on lung regeneration and the role of angiogenic signaling involving vascular endothelial growth factor (VEGF). Eight-week-old male C57BL/6J mice were randomized to receive intratracheal instillation of either LPS or isovolumetric phosphate buffered saline as a vehicle control. Mice were observed at a single follow-up time-point that was either short-term (24 h or 4 days) or long-term (7 days or 4 weeks). On pulmonary function testing, LPS-treated mice had increased compliance at 4 weeks post-instillation, which correlated with decreased vascularization and with time-dependent, progressive decrease in alveolarization. Treadmill exercise tolerance testing demonstrated impaired performance at 24 h, 4 days and 4 weeks following LPS exposure. On lung protein analysis, LPS instillation decreased VEGF expression at up to 4 weeks, and decreased activation of its key receptor, VEGFR2 at 7 days and 4 weeks post-instillation. Together, these data provide insight on long-term pulmonary functional outcomes 4 weeks after ALI and identify angiogenic proteins as possible therapeutic targets following lung injury.

Indexed as

Acute Lung InjuryLipopolysaccharidesAnimalsDown-RegulationLungMaleMiceMice, Inbred C57BLVascular Endothelial Growth Factor ALipopolysaccharidesVascular Endothelial Growth Factor A

Identifiers

PMID35715592
PMCPMC9205148
OpenAlexW4283014351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.